Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The Therapeutic Apheresis Database in the Catalan Region (AfTerCat) was developed to consolidate and standardize data collection for therapeutic apheresis procedures across public and private institutions in Catalonia. Covering procedures performed from 2019 to 2023 in 21 apheresis units, the registry captures data on plasma treatments, cell therapies, and cytapheresis procedures, with over 26,000 recorded entries. Variations in workload across public and private institutions were noted, influencing resource needs and operational costs. By streamlining manual data collection and planning future automation, the AfTerCat registry aims to provide crucial insights for healthcare administrators in optimizing resource allocation, managing procedure costs, and supporting evidence-based policy decisions. The registry's integration into the Organització Catalana de Trasplantaments (OCATT) digital transformation initiative highlights its potential to impact health policy through improved data centralization and real-time analysis. This project serves as a foundational step toward efficient health system planning and cost management in the growing field of therapeutic apheresis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12060802 | PMC |
| http://dx.doi.org/10.1159/000545202 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advancements in Cytomegalovirus Management Among Solid Organ Transplant Recipients: Insights From the ESOT CMV Workshop 2023.
Transpl Int
September 2025
Unit for Heart Failure and Transplantation, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Cytomegalovirus (CMV) infection poses significant challenges in solid organ transplant (SOT) recipients, impacting graft outcomes, morbidity, and in some cases survival. The ESOT CMV Workshop 2023 convened European experts to discuss current practices and advances in the management of CMV with the aim of improving the quality of life of transplant recipients. Discussions covered crucial areas such as preventive strategies, diagnostic challenges, therapeutic approaches, and the role of cell-mediated immunity (CMI) monitoring.
View Article and Find Full Text PDFAcoustofluidic system for targeted antibody removal in transplantation: Enabling small-volume therapeutic apheresis.
Sci Adv
September 2025
Duke Transplant Center, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.
Antibody-mediated rejection is a leading cause of allograft failure and mortality in pediatric solid organ transplant recipients. Current apheresis systems require large blood volumes and are primarily designed for adults, making them unsuitable for children and small animals. These systems often indiscriminately remove both harmful and protective antibodies, increasing the risk of complications such as life-threatening infections.
View Article and Find Full Text PDFA Prospective Comparative Study of High-Yield Plateletpheresis Using Haemonetics MCS+, Trima Accel, and Spectra Optia Devices in a Resource-Constrained Setting.
J Clin Apher
October 2025
Department of Clinical and Chemical Pathology, Division of Transfusion Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt.
In a resource-constrained setting, maximizing plateletpheresis efficiency is critical. We believe leveraging advanced apheresis device software to enhance platelet yield, reduce consumables, and shorten procedure times offers significant advantages. This study compared Haemonetics, Trima, and Optia apheresis devices, analyzing donor and machine parameters.
View Article and Find Full Text PDFIn response: Approach to autologous stem cell harvesting and transplantation in patients with cold-agglutinin disease or cryoglobulins.
Transfusion
September 2025
Cellular and Molecular Therapies, NHS Blood and Transplant, Oxford, UK.
Impact of severe dyslipidemia on renal function: A cross-sectional study.
Medicine (Baltimore)
August 2025
Department of Nephrology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Renal dysfunction causes dyslipidemia, and the progression of kidney disease is associated with treatment-requiring lipid disorders. However, there is little data on the association between the severity of dyslipidemia and various treatment modalities with renal function. A total of n = 214 prevalent patients from a lipidology and nephrology practice were investigated in an unicentric cross-sectional study and divided into 4 groups based on the severity and therapeutic regimen of an existing lipid metabolism disorder: a lipid apheresis-treated group (LA), a drug-treated group (MG), a control group (CG) that included patients with lipid disorder not needing any treatment, and a diabetes group that comprised all diabetes patients.
View Article and Find Full Text PDF